Verastem, Inc. (VSTM) analyst actions
Rating and price-target actions on VSTM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VSTM overview →
2 measured VSTM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer | Press release | +2.75% | -12.90% | |
| Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer | Press release | — | +9.73% |
Keep exploring
More VSTM: earnings → · SEC filings → · VSTM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Zai Lab Limited - American Depositary Shares (ZLAB) | 415 | 0.00% | 49% |
| Bausch Health Companies Inc. (BHC) | 412 | +0.06% | 50% |
| Alphatec Holdings, Inc. (ATEC) | 409 | -0.18% | 45% |
| Align Technology, Inc. (ALGN) | 407 | -0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.